Sun Pharma To Acquire Ranbaxy In $4 Billion Deal
Advertisement
MUMBAI: Sun Pharma and Ranbaxy Laboratories announced that they have entered into definitive agreements pursuant to which the former will acquire 100% of Ranbaxy in an all-stock transaction. The deal being termed as a "landmark transaction", has been estimated at $4 billion.
Under terms of the agreed deal, Ranbaxy shareholders will get 0.8 of aSun Pharmaceutical share for each Ranbaxy share they own. The exchange ratio represents an implied value of Rs 457 for each Ranbaxy share, a premium of 18% to Ranbaxy’s 30-day volume-weighted average share price and a premium of 24.3% to Ranbaxy's 60-day volume-weighted average share price, in each case, as of the close of business on April 4, 2014, said the statement.
The combination of Sun Pharma and Ranbaxy will be the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India.
The merged entity would create a newmarket leader in the immensely fragmented Rs 75,000 crore domestic pharma market, with the company commanding close 9.3% market share , according to AIOCD AWACS.
Advertisement
Advertisement
Under terms of the agreed deal, Ranbaxy shareholders will get 0.8 of a
The combination of Sun Pharma and Ranbaxy will be the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India.
The merged entity would create a new
Advertisement
- Fresh photographs of Milky Way’s black hole Sgr A* reveal strong, twisted magnetic field similar to M87*
- 8 Lesser-known places to explore in Himachal Pradesh
- Markets end FY24 on buoyant note amid positive global cues
- SRM Contractors IPO allotment – How to check allotment, GMP, listing date and more
- Rupee falls 6 paise to settle at 83.39 against US dollar